BeiGene’s (to be BeOne Medicines) Tevimbra Secures the EC’s Approval as a 1L Treatment of Esophageal Squamous Cell Carcinoma and G/GEJ Cancer
Shots:
- The EC has approved Tevimbra + Pt-based CT as well as Pt & fluoropyrimidine-based CT as a 1L treatment of unresectable, locally advanced or metastatic ESCC & G/GEJ cancer, respectively, with PD-L1 expression & TAP ≥5%
- ESCC approval was based on P-III (RATIONALE-306) study in 649 patients, showing OS benefit with mOS of 17.2 vs 10.6mos. & 34% reduced death risk. In the PD-L1 ≥5% patients, 3yrs. OS was improved with mOS of 19.1 vs 10mos. & 38% risk reduction
- G/GEJ cancer approval was based on P-III (RATIONALE-305) study in 997 patients, depicting OS benefit with mOS of 15 vs 12.9mos. & 20% reduced death risk. In the PD-L1 ≥5% patients, mOS was 16.4 vs 12.8mos. with a 29% risk reduction
Ref: BeiGene | Image: BeiGene
Related News:- BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
